title: Cap dependent translation contributes to resistance of myeloma cells to bortezomib.
abstract: Multiple myeloma (MM) is the second most predominant blood malignancy. Proteasome inhibitors like bortezomib have increased life expectancy, but eventually patients develop resistance to therapy. It was proposed that bortezomib acts through the induction of the Unfolded Protein Response (UPR), i.e., accumulation of misfolded proteins causing a lethal stress response. By this theory, increasing the proteasome load by the stimulation of translation may worsen the UPR. Here we evaluated the crosstalk between translation and bortezomib toxicity in both bortezomib sensitive and resistant cells. We found that bortezomib toxicity does not correlate with induction of proapoptotic eIF2α phosphorylation, but rather caused a late reduction in initiation of translation. This effect was accompanied by dephosphorylation of the mTORC1 target 4E-BP1. Infection of myeloma cells with constitutively dephosphorylated 4E-BP1, worsened bortezomib induced cell death. Since mTORC1 inhibitors cause pharmacological inhibition of 4E-BP1 phosphorylation, we tested whether they could act synergistically with bortezomib. We found that both rapamycin, a specific mTORC1 blocker, and PP242 a mTOR antagonist induce the arrest of myeloma cells irrespective of bortezomib sensitivity. Sensitivity to mTOR inhibitors has been associated to the levels of eIF4E/4E-BPs. We found that levels of eIF4E and 4E-BPs are variable among patients, and that 15% of myeloma patients have increased levels of 4E-BP1/2. Primary cells of myeloma retain sensitivity to mTOR inhibition, when plated on stromal cells. We propose that translational load does not contribute to bortezomib-induced death, but rather mTOR targeting may be successful in bortezomib resistant patients, stratified for eIF4E/4EBPs.
authors.affiliation: San Raffaele Scientific Institute; Milan, Italy; DISIT; Alessandria, Italy.
authors.forename: Marilena
authors.initials: M
authors.lastname: Mancino
authors.affiliation: MRC Toxicology Unit; Leicester, UK.
authors.forename: Stefano
authors.initials: S
authors.lastname: Grosso
authors.affiliation: Istituto di Ematologia "Seràgnoli"; DIMES; Bologna, Italy.
authors.forename: Carolina
authors.initials: C
authors.lastname: Terragna
authors.affiliation: Istituto di Ematologia "Seràgnoli"; DIMES; Bologna, Italy.
authors.forename: Enrica
authors.initials: E
authors.lastname: Borsi
authors.affiliation: Istituto di Ematologia "Seràgnoli"; DIMES; Bologna, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.affiliation: San Raffaele Scientific Institute; Milan, Italy; DISIT; Alessandria, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Biffo
keywords: 4E-BP1; 4E-BP2; ERK; MM.1S; U266; eIF2α; eIF4E
references.citation: Blood. 2012 Jul 5;120(1):9-19
references.pmid: 22498745
references.citation: Genes Dev. 2004 Aug 15;18(16):1926-45
references.pmid: 15314020
references.citation: J Clin Oncol. 2013 Sep 10;31(26):3279-87
references.pmid: 23897961
references.citation: Mol Cancer Ther. 2013 Jun;12(6):831-43
references.pmid: 23729400
references.citation: Int Rev Cell Mol Biol. 2008;268:1-37
references.pmid: 18703402
references.citation: Cancer Cell. 2007 Aug;12 (2):131-44
references.pmid: 17692805
references.citation: Exp Hematol. 2007 Oct;35(10):1550-61
references.pmid: 17889722
references.citation: Cancer Res. 2007 Feb 15;67(4):1783-92
references.pmid: 17308121
references.citation: Haematologica. 2012 Jan;97(1):64-72
references.pmid: 21993678
references.citation: Haematologica. 2013 Jun;98(6):971-9
references.pmid: 23242599
references.citation: N Engl J Med. 2004 Oct 28;351(18):1860-73
references.pmid: 15509819
references.citation: PLoS One. 2011;6(12):e29136
references.pmid: 22216185
references.citation: Science. 2013 Jul 26;341(6144):1236566
references.pmid: 23888043
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9
references.pmid: 12391322
references.citation: Nat Rev Mol Cell Biol. 2009 May;10(5):307-18
references.pmid: 19339977
references.citation: Blood. 2010 Nov 25;116(22):4560-8
references.pmid: 20686120
references.citation: Genes Dev. 1998 Apr 1;12(7):982-95
references.pmid: 9531536
references.citation: Leuk Res. 2009 Nov;33(11):1475-80
references.pmid: 19261329
references.citation: Nature. 2011 Mar 24;471(7339):467-72
references.pmid: 21430775
references.citation: Cancer Res. 2006 Jan 1;66(1):184-91
references.pmid: 16397231
references.citation: J Clin Invest. 2010 Aug;120(8):2858-66
references.pmid: 20664172
references.citation: Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
references.pmid: 22251901
references.citation: Lancet Oncol. 2011 Mar;12(3):263-72
references.pmid: 21345726
references.citation: Clin Cancer Res. 2013 Jul 1;19(13):3337-44
references.pmid: 23515406
references.citation: Cancer Res. 2009 Feb 15;69(4):1545-52
references.pmid: 19190324
references.citation: Blood. 2010 Apr 29;115(17 ):3541-52
references.pmid: 20053756
references.citation: Semin Cell Dev Biol. 2005 Feb;16(1):3-12
references.pmid: 15659334
references.citation: Am J Clin Oncol. 2014 Jun;37(3):266-71
references.pmid: 23241507
references.citation: J Clin Invest. 2008 Sep;118(9):3065-74
references.pmid: 18725988
references.citation: Blood. 2009 Mar 26;113(13):3040-9
references.pmid: 19164601
references.citation: Cancer Res. 2012 Dec 15;72(24):6468-76
references.pmid: 23100465
references.citation: Blood. 2006 Jun 15;107(12):4907-16
references.pmid: 16507771
references.citation: Leuk Res. 2012 Jul;36(7):912-20
references.pmid: 22560334
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 19;100(17 ):9946-51
references.pmid: 12902539
references.citation: J Biol Chem. 2007 May 11;282(19):14056-64
references.pmid: 17360704
references.citation: Blood. 2008 Mar 15;111(6):3131-6
references.pmid: 18174379
references.citation: Blood. 2011 Feb 10;117(6):1998-2004
references.pmid: 21149634
references.citation: Cancer. 2004 Apr 15;100(8):1578-89
references.pmid: 15073843
references.citation: Blood. 2011 Dec 22;118(26):6860-70
references.pmid: 22045983
references.citation: Discov Med. 2011 Dec;12(67):471-80
references.pmid: 22204764
references.citation: Cancer Res. 2005 Dec 15;65(24):11658-66
references.pmid: 16357177
references.citation: PLoS Biol. 2009 Feb 10;7(2):e38
references.pmid: 19209957
references.citation: Blood. 2008 Mar 1;111(5):2516-20
references.pmid: 17975015
references.citation: Nat Rev Cancer. 2007 Aug;7(8):585-98
references.pmid: 17646864
references.citation: Oncogene. 2007 Mar 22;26(13):1932-40
references.pmid: 17001314